Nurix Therapeutics, Inc.
NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for thā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$23.22
Price+0.04%
$0.01
1Y
Price
Market Cap
$2.410b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-950.5%
EBITDA Margin-990.1%
Net Profit Margin-1089.3%
Free Cash Flow Margin-950.5%
EBITDA Margin-990.1%
Net Profit Margin-1089.3%
Free Cash Flow MarginRevenue
$36.766m
-56.2%
1y CAGR-10.5%
3y CAGR+17.0%
5y CAGREarnings
-$341.351m
-29.1%
1y CAGR-33.4%
3y CAGR-20.0%
5y CAGREPS
-$3.45
-13.1%
1y CAGR-9.2%
3y CAGR+0.2%
5y CAGRBook Value
$402.627m
$535.540m
Assets$132.913m
Liabilities$58.143m
DebtDebt to Assets
10.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$304.527m
-15.6%
1y CAGR-54.3%
3y CAGR-28.8%
5y CAGRNo items found.
Press Releases
Statements and updates from the company